EXELIXIS, INC.EXELEarnings & Financial Report
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
EXEL Q4 2026 Key Financial Metrics
营收
$598.7M
毛利润
$572.2M
营业利润
$235.2M
净利润
$244.5M
毛利率
95.6%
营业利润率
39.3%
净利率
40.8%
同比增长
5.6%
EPS
$0.89
资金流向
EXELIXIS, INC. Q4 2026 Financial Summary
EXELIXIS, INC. reported revenue of $598.7M (up 5.6% YoY) for Q4 2026, with a net profit of $244.5M (up 74.8% YoY) (40.8% margin). Cost of goods sold was $26.5M, operating expenses totaled $337.0M.
Key Financial Metrics
| Total Revenue | $598.7M |
|---|---|
| Net Profit | $244.5M |
| Gross Margin | 95.6% |
| Operating Margin | 39.3% |
| Report Period | Q4 2026 |
EXELIXIS, INC. Annual Revenue by Year
EXELIXIS, INC. annual revenue history includes year-by-year totals (for example, 2026 revenue was $2.3B). Click any linked year to see what changed vs the prior 10-K.
EXELIXIS, INC. Quarterly Revenue & Net Profit History
EXELIXIS, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2026 | $598.7M | +5.6% | $244.5M | 40.8% |
| Q3 2026 | $597.8M | +10.8% | $193.6M | 32.4% |
| Q2 2026 | $568.3M | -10.8% | $184.8M | 32.5% |
| Q1 2026 | $555.4M | +30.6% | $159.6M | 28.7% |
| Q4 2025 | $566.8M | +18.2% | $139.9M | 24.7% |
| Q3 2025 | $539.5M | +14.3% | $118.0M | 21.9% |
| Q2 2025 | $637.2M | +35.6% | $226.1M | 35.5% |
| Q1 2025 | $425.2M | +4.0% | $37.3M | 8.8% |
利润表
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $425.2M | $637.2M | $539.5M | $566.8M | $555.4M | $568.3M | $597.8M | $598.7M |
| 同比增长 | 4.0% | 35.6% | 14.3% | 18.2% | 30.6% | -10.8% | 10.8% | 5.6% |
资产负债表
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $2.80B | $2.77B | $2.96B | $2.95B | $2.84B | $2.68B | $2.82B | $2.84B |
| 总负债 | $675.7M | $653.4M | $684.9M | $703.5M | $706.2M | $644.5M | $662.8M | $683.1M |
| 股东权益 | $2.13B | $2.12B | $2.28B | $2.24B | $2.13B | $2.03B | $2.16B | $2.16B |
现金流量表
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $68.8M | $119.5M | $271.3M | $240.3M | $211.4M | $49.0M | $290.3M | $333.5M |